To Evaluate Real-world Safety, Effectiveness and Appropriate Use of Micatrio® Combination Tablets Treatment in Patients With Hypertension

NCT03021265 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 676

Last updated 2020-05-12

Study results available
· View outcomes & findings →

Summary

Study to evaluate real-world safety, effectiveness and appropriate use of Micatrio® Combination Tablets treatment in patients with hypertension

Conditions

Interventions

DRUG

T80/A5/H12.5 FDC

Drug

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim · Boehringer Ingelheim

  • Rie Ikeda, +81364172200 · [email protected]

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-20
Primary Completion
2019-04-11
Completion
2019-04-11

Countries

  • Japan

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03021265 on ClinicalTrials.gov